HC Wainwright Comments on XOMA’s Q1 Earnings (NASDAQ:XOMA)

XOMA Co. (NASDAQ:XOMA) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of XOMA in a note issued to investors on Wednesday, March 19th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will earn ($0.20) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $104.00 target price on the stock. The consensus estimate for XOMA’s current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for XOMA’s Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at $0.23 EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at $0.12 EPS.

Separately, StockNews.com cut XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th.

XOMA Stock Up 0.8 %

XOMA opened at $21.06 on Friday. XOMA has a 12 month low of $19.92 and a 12 month high of $35.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The stock has a market cap of $248.15 million, a P/E ratio of -6.05 and a beta of 1.00. The stock’s 50 day moving average price is $24.45 and its 200 day moving average price is $27.20.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). The company had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%.

Insider Activity at XOMA

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.20% of the stock is owned by insiders.

Hedge Funds Weigh In On XOMA

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after purchasing an additional 1,138 shares in the last quarter. Woodline Partners LP boosted its stake in XOMA by 63.9% during the 4th quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock valued at $4,107,000 after purchasing an additional 60,927 shares in the last quarter. State Street Corp boosted its stake in XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 1,754 shares in the last quarter. Eversept Partners LP boosted its stake in XOMA by 1.2% during the 4th quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company’s stock valued at $2,508,000 after purchasing an additional 1,128 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in XOMA by 1.5% during the 4th quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company’s stock valued at $2,396,000 after purchasing an additional 1,340 shares in the last quarter. 95.92% of the stock is owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.